UNSPSC 51111645: Pralatrexate

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C23H23N7O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8Q8I19Q20, more generally known as pralatrexate. European Medicines Agency schedules pralatrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32989. The term PRALATREXATE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.

Most nations schedule pralatrexate under HS 29335995 and SITC 51576. As of Q4 2014, PRALATREXATE remains the US FDA Preferred Term for this commodity. Pralatrexate bears US NLM identifiers UMLS ID C0879404 and NCI Concept Code C2250. SMILES: C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.

UNSPSC 51111645 Pralatrexate, a Commodity code, covers the procurement of pralatrexate, a folate analog antimetabolite chemotherapy drug used in the treatment of peripheral T-cell lymphoma. State and local governments acquire pralatrexate through this code primarily for hospital pharmacy departments, correctional health services, and public health agencies that provide oncology treatment or maintain formulary stocks. The drug is sourced as a manufactured pharmaceutical product, typically supplied through established vendors or group purchasing agreements rather than as a custom-compounded service.

The source provided contains no recent state and local contract opportunities posted under UNSPSC 51111645. Without posted solicitations, the issuing-body mix, geographic spread, and representative opportunities cannot be characterized from current activity.